Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 11fludarabine phosphate 8fludarabine 8apixaban 8Mycophenolic Acid 6Melphalan 6Busulfan 6Whole-Body Irradiation 4Tacrolimus 4Rivaroxaban 4Filgrastim 4Biopsy 4thymoglobulin 3X-Rays 3Specimen Handling 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Hematopoietic Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Enoxaparin 3Bone Marrow Transplantation 3Azacitidine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2olaparib 2Tretinoin 2Stem Cell Transplantation 2Mesna 2Injections 2Heparin, Low-Molecular-Weight 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × cedazuridine × Classical hematology × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡